What is known about the use of efgartigimod alfa during pregnancy?

There are no data on efgartigimod alfa use during pregnancy; it may reach the foetus and reduce newborn passive immunity, so treatment should be considered only if clinical benefit outweighs risks, and risks and benefits of live/live-attenuated vaccines in infants exposed in utero should be considered.